RETRACTED: Long Noncoding RNA FOXD2-AS1 Promotes the Malignancy of Cervical Cancer by Sponging MicroRNA-760 and Upregulating Hepatoma-Derived Growth Factor
A Retraction of the Original Research Article
Long noncoding RNA FOXD2-AS1 promotes the malignancy of cervical cancer by sponging microRNA-760 and upregulating hepatoma-derived growth factor
Dou X, Zhou Q, Wen M, Xu J, Zhu Y, Zhang S and Xu X (2020). Front. Pharmacol. 10:1700. doi: 10.3389/fphar.2019.01700
Following publication, concerns were raised regarding the validity of the data in the article. The authors failed to provide the raw data or a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies. Given the concerns, and the lack of raw data, the editors no longer have confidence in the findings presented in the article.
This retraction was approved by the Chief Editors of Frontiers in Pharmacology and the Chief Executive Editor of Frontiers. The authors have agreed to the retraction.
Citation: Frontiers Editorial Office (2023) Retraction: Long noncoding RNA FOXD2-AS1 promotes the malignancy of cervical cancer by sponging microRNA-760 and upregulating hepatoma-derived growth factor. Front. Pharmacol. 13:1129216. doi: 10.3389/fphar.2022.1129216
Received: 21 December 2022; Accepted: 21 December 2022;
Published: 05 January 2023.
Approved by:
Olivier Feron, Université catholique de Louvain, BelgiumCopyright © 2023 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Editorial Office, research.integrity@frontiersin.org